PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.47%
Both companies show declining cash positions (-7.47% vs AGEN's -15.15%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.47%
Cash + STI yoy 0.5-0.75x AGEN's -14.41%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.14%
0.5-0.75x AGEN's -12.50%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-20.34%
Below half AGEN's 16.29%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
Below half of AGEN's 12.57%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
1.25-1.5x AGEN's -5.29%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
-4.95%
Less than half of AGEN's 13.31%. David Dodd sees a more disciplined AP approach or lower volume.
-36.48%
Less than half of AGEN's 1847.94%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-627.15%
Below half of AGEN's 8.87%. Michael Burry suspects a big gap in pre-sales traction.
-89.58%
Exceeding 1.5x AGEN's -7.35%. Michael Burry suspects ballooning short-term obligations vs. competitor.
-16.33%
Less than half of AGEN's 3.90%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.33%
Above 1.5x AGEN's -4.03%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-16.34%
Above 1.5x AGEN's -1.05%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-2.01%
0.5-0.75x AGEN's -3.24%. Martin Whitman is wary of weaker retention or lower profitability.
100.00%
Less than half of AGEN's -34.99%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to AGEN's zero value, indicating worse performance.
-6.40%
Below half AGEN's -54.36%. Michael Burry sees potential underperformance in building shareholder capital.
-7.25%
1.25-1.5x AGEN's -5.29%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
-36.45%
Less than half of AGEN's 10.34%. David Dodd sees less overall debt expansion vs. competitor.
7.35%
Less than half of AGEN's 21.51%. David Dodd sees better deleveraging or stronger cash buildup than competitor.